Neurocrine Biosciences (NCRN) Q4 Profit Up 12% to $132M

Net profit for Neurocrine Biosciences Inc (NCRN) rose to $132 million in Q4 2025, a 12% increase from $118 million in the same period of 2024. Revenue climbed 21% to $448 million, driven by strong sales of its Alzheimer’s disease treatment, lecanemab. The company attributed the results to higher dosing of lecanemab and expanded access in key markets. Earnings per share for the quarter were $1.24, up from $1.12 in Q4 2024.